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SUMMARY
Most human cancers arise from stem and progenitor
cells by the sequential accumulation of genetic and
epigenetic alterations, while cancer modeling typi-
cally requires simultaneous multiple oncogenic
events. Here, we show that a single p53 mutation,
despite causing no defect in the mouse brain, pro-
moted neural stem and progenitor cells to spontane-
ously accumulate oncogenic alterations, including
loss of multiple chromosomal (chr) regions syntenic
to human chr10 containing Pten, forming malignant
gliomas with PI3K/Akt activation. Rictor/mTORC2
loss inhibited Akt signaling, greatly delaying and
reducing glioma formation by suppressing glioma
precursors within the subventricular zone stem cell
niche. Rictor/mTORC2 loss delayed timely differ-
entiation of granule cell precursors (GCPs) during
cerebellar development, promoting sustained GCP
proliferation and medulloblastoma formation, which
recapitulated critical features of TP53 mutant sonic
hedgehog (SHH) medulloblastomas with GLI2 and/
or N-MYC amplification. Our study demonstrates
that Rictor/mTORC2 has opposing functions in
neural stem cells and GCPs in the adult and the
developing brain, promoting malignant gliomas
and suppressing SHH-medulloblastoma formation,
respectively.
INTRODUCTION
More than 90% of human glioblastomas (GBMs) are primary or
de novo GBMs with no evidence of pre-existing lower-grade
lesions (Louis et al., 2016). Rapid clinical course presents a
tremendous challenge in defining the temporal sequence and
functional outcomes of accumulating each of the oncogenic
driver alterations in neural stem or progenitor cells during the
development of primary GBMs. One recent study using a bioin-
formatics approach inferred that most somatic TP53 mutations
(90.5%) were clonal, occurring in every tumor cell of the GBM
samples analyzed and thus representing one of the early found-
ing events in TP53 mutant primary GBMs (Kim et al., 2015).
Moreover, individuals with Li-Fraumeni syndrome (LFS) carrying
germline TP53mutations have increased risks of developingma-
lignant gliomas and GBMs as well as medulloblastomas (MBs),
the most common malignant brain tumor in children (Louis
et al., 2016). Consistent with an initiating role of TP53 mutations
in human brain tumorigenesis, conditional inactivation of p53 in
the mouse brain induces malignant gliomas and GBMs and,
less frequently, MBs (Wang et al., 2009; Zheng et al., 2008).
Both clinical observations and mouse modeling studies suggest
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Figure 1. p53-Mutant Malignant Gliomas Exhibit Unique Genomic Alterations Consistent with Human Primary GBMs
(A and B) Gene expression profiles of the p53-mutant-driven malignant gliomas with or without targeted Nf1 deletions are compared to those of human GBM
subgroups (A) and different cell lineages in the brain (B). High single-sample gene set enrichment analysis (ssGSEA) score (red) indicates strong similarity, while
low scores (blue) indicate dissimilarity. FB, forebrain; CB, cerebellum.
(C and D) The GISTIC method was used to detect both local and broad CNAs in 23 GEMmalignant gliomas. GISTIC scores and FDRs are indicated in the upper
and lower parts of the x axes, respectively. Chromosomal regions with amplification peaks (C) or deletion peaks (D) are listed. Some frequently amplified and
deleted genes in both GEM malignant gliomas and TP53 mutant human GBMs are highlighted in red and blue, respectively.
(E) Synteny map comparing the human chr10q with the mouse chr19 and chr7.
(legend continued on next page)
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that p53 plays a critical role in the initiation of both GBMs and
MBs. However, loss of p53 alone leads to little or no effect on
the mouse brain during development or in adulthood (Chow
et al., 2011; Shingu et al., 2017; Wang et al., 2009; Zheng
et al., 2008). Therefore, this conditional neural-specific p53-
mutant model must accumulate cooperating oncogenic alter-
ations in cells with sustained proliferative potentials—neural
stem or progenitor cells—to drive malignant transformation in
the brain (Ihrie and Alvarez-Buylla, 2011; Wang et al., 2009,
2012).
Loss of the long arm of chromosome 10 (chr10q) appears to be
a common mechanism, occurring in almost all primary GBMs,
but less frequently in secondary GBMs that arise from pre-exist-
ing lower-grade gliomas harboring isocitrate dehydrogenase 1
(IDH) mutations (Brennan et al., 2013; Louis et al., 2016; Sturm
et al., 2014). Although loss of a relatively large region of chr10q
suggests the existence of multiple tumor-suppressor genes,
the most studied is the PTEN tumor suppressor, which nega-
tively regulates the phosphoinositide 3-kinase (PI3K) signaling
pathway (Janku et al., 2018; Ozawa et al., 2014). Loss of PTEN
in chr10q is consistent with the observation that most GBMs in
humans (>80%) exhibit activation of AKT signaling, the best
characterized downstream effector of the PI3K/PTEN signaling
pathway (Janku et al., 2018; Wang et al., 2004). AKT requires
two phosphorylation events for full activation: (1) PDK1 phos-
phorylates AKT at threonine-308 (AKTThr308) and (2) the mecha-
nistic target of rapamycin complex 2 (mTORC2) is the major
kinase that phosphorylates AKT at serine-473 (AKTSer473) (Janku
et al., 2018; Laplante and Sabatini, 2012; Wu et al., 2014). Given
its critical functions onmetabolic reprogramming and drug resis-
tance, mTORC2 has recently been emerging as an attractive
therapeutic target for human GBMs (Masui et al., 2013, 2015;
Wu et al., 2014). It has been shown that loss of RICTOR/Rictor,
an essential subunit of mTORC2, is sufficient to inhibit phosphor-
ylation of AKT/Akt at serine-473, inactivate AKT/Akt, and, conse-
quently, prevent tumor formation in several Pten-loss-driven
mouse cancer models, including prostate cancer and leukemia,
as well as in a Drosophila glioma model (Guertin et al., 2009;
Kalaitzidis et al., 2012; Magee et al., 2012; Read et al., 2009).
However, whether Rictor/mTORC2 signaling in neural stem
or progenitor cells is required for the formation of primary GBM
remains to be determined.
In contrast to GBMs, mutations in PTEN or other compo-
nents of the PI3K signaling pathway are rare in MBs, and
more important, almost no phosphorylated AKTSer473 (<5%)
was observed in pediatric sonic hedgehog-MBs (SHH-MBs),
the only MB subtype observed in individuals with LFS (Kool
et al., 2014; Northcott et al., 2012). These intriguing observa-
tions raise the possibility of whether mTORC2/AKT signaling
has opposing effects on the formation of TP53 mutant primary
GBMs versus SHH-MBs.
RESULTS
p53-Mutant GEM Gliomas Spontaneously Acquire
Common Genomic Alterations Observed in Human
Primary GBMs
Using a Cre transgenic line controlled by the human glial fibrillary
acidic protein promoter (hGFAP-cre), we previously developed
three genetically engineered mouse (GEM) gliomamodels driven
by a conditional in-frame deletion of exons 5 and 6 of the p53
gene (1) alone (hGFAP-cre;p53E5–6/E5–6) or (2) in combination
with a germline heterozygous neurofibromatosis type 1 (Nf1) mu-
tation (hGFAP-cre;p53E5–6/E5–6;Nf1+/), and (3) a germline p53
null and a conditional Nf1 mutation on the same chromosome
(hGFAP-cre;cis-p53+/;Nf1+/flox) (Wang et al., 2009, 2012; Zhu
et al., 2005). All three GEM models frequently developed malig-
nant gliomas, which harbor homozygous p53 deletion with or
without additionally targeted Nf1 deletion, hereafter referred to
as p53D5–6/D5–6, p53D5–6/D5–6Nf1/ and p53/Nf1/, respec-
tively. These malignant gliomas exhibited critical histopatholog-
ical characteristics of human high-grade gliomas (grades III and
IV), including nuclear atypia and frequent mitotic figures, with
approximately 40% showing necrosis and/or microvascular pro-
liferation, the diagnostic features of human GBM (Louis et al.,
2016; Wang et al., 2009; Zhu et al., 2005).
The gene expression profiles of all but two of the p53/Nf1/
malignant gliomas exhibited a dominant proneural signature of
human GBMs (Figure 1A) (Verhaak et al., 2010). The two excep-
tions with a classical signature uniquely exhibited EGFR amplifi-
cation on chr11 (human chr7), similar to most of the human clas-
sical GBMs with EGFR alterations (Figures 1A and S1A–S1C)
(Verhaak et al., 2010). Consistent with human proneural GBMs,
all of the GEM proneural gliomas exhibited the gene expression
profile that is similar to oligodendrocyte precursor cells (OPCs),
which is characterized by high expression of Olig2 and Ascl1
(Figure 1B; data not shown) (Verhaak et al., 2010). Sanger
sequencing did not reveal somatic mutations of Idh1 or Idh2 in
these GEM gliomas (n = 7). The gene expression profiles of these
gliomas did not consistently resemble IDH mutant GBMs with a
hypermethylated phenotype or glioma CpG island methylated
phenotype (G-CIMP) (Figure 1A) (Baysan et al., 2012; Noush-
mehr et al., 2010; Ozawa et al., 2014). Together, these results
demonstrate that p53- and p53/Nf1-mutant-driven malignant
gliomas genetically and molecularly resemble the proneural
subtype of IDH-wild-type (IDH-WT) primary GBMs, but not IDH
mutant G-CIMP+ secondary GBMs in humans.
To determine oncogenic driving events during p53- and p53/
Nf1-mutant-driven gliomagenesis, we analyzed the copy-num-
ber alterations (CNAs) in a total of 23 malignant gliomas and
GBMs. We applied Genomic Identification of Significant Targets
in Cancer (GISTIC) analysis, a de facto community standard for
characterizing local and broad CNAs in human cancers (Mermel
(F) Genome plot displaying the frequencies of the copy-number gains (red) and losses (blue) in these 23 GEM malignant gliomas. Segments of the mouse chr19
and chr7 (syntenic to human chr10q) and mouse chr7 (syntenic to human chr19) are indicated with dashed-line boxes.
(G and H) qPCR experiments for CNA analysis were performed in an additional cohort of GEM malignant gliomas. Plots show the ratio of copy number of Pten
(gene on chr10) and Dmbt1 (gene on chr7) (G) and two distinct exons of the Pten gene (H) in tumor samples separately. Black boxes indicate the specific deletion
events, and the red box indicates malignant gliomas, where Pten exon 5 (but not exon 9) is deleted by the Cre/LoxP strategy.
See also Figure S1 and Table S1.
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Figure 2. Rictor Deletion Inhibits p53-Mutant-Driven Malignant Glioma Formation
(A and B) Kaplan-Meier survival curves of mice sacrificed because of end-stage brain tumors (A) or end-stage malignant gliomas (B) in three models. Black
dashed line indicates 1 year. Red dashed-line box in (A) indicates a comparable survival rate.
(C) The frequency of malignant gliomas and MBs.
(D and E) Mutant mice at age 6–7 months were injected with BrdU for proliferation assay. Expansion of the glioma precursor population around the corpus
callosum (D) and rostral migratory stream (E) is illustrated by p53 and BrdU staining. Yellow dashed-line area indicates the p53D5–6+ cluster. Ctx, cerebral cortex;
CC, corpus callosum; OB, olfactory bulb; RMS, rostral migratory stream; LV, lateral ventricle.
(legend continued on next page)
466 Cell Reports 24, 463–478, July 10, 2018
et al., 2011). We found that both GEM p53-mutant gliomas and
human TP53-mutant GBMs exhibited significantly fewer amplifi-
cations than deletions (false discovery rate [FDR] 0.25) (Figures
1C, 1D, S1D, and S1E). In GEM gliomas, approximately 1%
and 16% of the genome (excluding the sex chromosome) was
affected by amplifications and deletions, respectively. This
pattern is remarkably similar to that observed in human TP53
mutant IDH-WT GBMs—1% and 12% of the genome affected
by amplifications and deletions, respectively. All 17 amplification
peaks identified in GEM gliomas across chr4, -6, -7, -12, and -14
were focal (14/17 <2 MBs), a pattern reminiscent of human
GBMs (Figure 1C; Table S1) (Brennan et al., 2013). Cross-
referencing with human data, we found a peak in chr6 syntenic
to human chr7, the most frequently gained chromosome in hu-
man IDH-WT but not IDH mutant GBMs (Figures 1C, S1A, and
S1D). The chr6 amplicon encompassed Met, amplified in three
cases. Other significant oncogenes in the amplification peaks
included Ccnd1 and Ccnd2 (Figure 1C; Table S1). Of note,
GISTIC analysis did not identify a peak centering on Egfr, which
is also syntenic to human chr7, but it was amplified in only two
cases without Met amplification and identified by a targeted
approach (Figures S1A–S1C). These results suggest that individ-
ual GEM p53-mutant gliomas acquire different oncogenic alter-
ations, including Met or Egfr, driving malignant transformation
following p53 inactivation (Figure S1B).
Deletions in these GEM gliomas were largely contributed by
broad losses of chr7, -9, and -19 (Figures 1D, S1D, and S1E).
Because mouse and human chromosomes are often not syn-
tenic, loss of chr9 was deleted in 13/23 GEM gliomas (57%)
but mapped to multiple human chromosomal regions, including
chr11q, -19p, -15q, -6q, and -3. Among them, chr11q was
deleted in 30% of human GBMs, and other syntenic regions
were also deleted, but less frequently (Brennan et al., 2013).
Loss of chr10q, the most frequent broad event found in >90%
of IDH-WT GBMs, is mapped into multiple mouse chromo-
somes, including chr19 and the distal end of chr7 (Figures 1E,
1F, and S1D). It was most striking that the deletion of chr19,
the distal end of chr7, or both were observed in 70%, 78%, or
65%of the 23GEM gliomas analyzed, respectively, thus recapit-
ulating one of the most prevalent chromosomal abnormalities in
human IDH-WT GBMs (Figures 1D–1F, S1D, and S1E). We
further used qPCR analysis on an independent cohort of 11
p53D5–6-mutant-driven malignant gliomas, of which 82%, 73%,
and 55% exhibited the loss of chr19, the distal end of chr7,
and both, respectively (Figure 1G). These results demonstrate
that the majority of p53D5–6-mutant-driven malignant gliomas,
regardless of the absence or presence of the Nf1 mutation,
exhibit concurrent loss of chr19 and the distal end of chr7,
both of which are syntenic to human 10q.
When a conditional heterozygous Pten mutation with a floxed
exon 5 (Pten+/E5) was introduced to the p53D5–6/D5–6 model, the
resultant p53D5–6/D5–6;Pten+/D mutant-driven gliomas exhibited
Cre-mediated deletion of exon 5 but not unfloxed exon 9 (Fig-
ure 1H) (Zheng et al., 2008). In contrast, the p53-mutant-driven
gliomas exhibited a reduction in both exons 5 and 9 of the
Pten gene as a result of chr19 loss, which was predicted by
both GISTIC and raw CNA data (Figure 1H). Similarly, high-grade
malignant gliomas induced by conditional inactivation of p53 and
Pten (with or without Rb) also did not exhibit the chr19 loss re-
ported in a previous study (Figure S1F) (Chow et al., 2011). These
results demonstrate that targeted deletion of Pten abrogates
chr19 loss, thus circumventing the selection of malignant glioma
cells with a hallmark of chromosomal abnormalities (chr10q loss)
in human primary GBMs.
Rictor/mTORC2 Deletion Delays p53-Mutant-Driven
Malignant Glioma Formation
Given the frequent loss of chr19/Pten and the activation of the
PI3K/Akt signaling pathway in these GEM malignant gliomas,
we analyzed the effects of the conditional loss of one or two al-
leles ofRictor in the p53D5–6-mutant brain tumormodel (hereafter
referred to as p53D5–6/D5–6Rictor+/D or p53D5–6/D5–6RictorD/D,
compared to p53D5–6/D5–6 mice) (Figure S3C). The loss of both al-
leles, not one allele of Rictor, significantly prolonged the lifespan
of p53D5–6/D5–6 mice with brain tumors (Figure 2A). Prolonged
lifespan (>50%) and long-term survivors (>12 months) were pre-
dominately observed in p53D5–6/D5–6RictorD/Dmice, whichmainly
resulted from a delay in the formation of malignant gliomas and
tumors outside the brain (Figures 2B, S2A, and S2B). The major-
ity of brain tumors were characterized as high-grade malignant
astrocytic gliomas, including GBMs with expression of GFAP
and Olig2, as well as high levels of p53D5–6-mutant protein (Fig-
ures 2C and S2C) (Louis et al., 2016). These results demonstrate
that Rictor deletion extends survival by delaying p53D5–6-
mutant-driven malignant glioma formation.
We have previously provided evidence that all malignant gli-
omas specifically accumulate high levels of mutant p53D5–6 pro-
tein, which appear to arise from p53D5–6+ glioma precursor cells
that emerge from the subventricular zone (SVZ) stem cell niche at
4–7 months of age (Ihrie and Alvarez-Buylla, 2011; Wang et al.,
2009). Highly proliferating cell clusters expressing high levels of
p53D5–6 protein were consistently identified in the corpus cal-
losum, the rostral migratory stream, and the olfactory bulb—
the areas associated with the SVZ stem cell niche, in 5 of 9
p53D5–6/D5–6brains analyzed at 6–7 months of age (Figures 2D–
2F). In contrast, only 1 of 9 age-matched p53D5–6/D5–6RictorD/D
brains had a similar p53D5–6/bromodeoxyuridine-positive
(BrdU+) cluster, which exhibited a significantly lower proliferation
(F and G) The total number of the p53D5–6+ cells scattered and/or clustered outside the germinal zone was quantified in p53D5–6/D5–6 and p53D5–6/D5–6RictorD/D
mice (F). The percentage of the proliferating p53D5–6+ cells was calculated using the samples that haveR20 p53D5–6+ cells (G).
(H and I) Tumor cell proliferation in malignant gliomas based on Ki67 staining is shown in (H) and quantified in (I).
(J) Western blot analyses of malignant gliomas from different GEM models. Normal cortical tissue was used as control (CTR), and two malignant gliomas that
harbored p53 and Pten mutations (described in Figure S3D) were included.
All of the quantification data are presented as means ± SEMs. The Mantel-Cox (log-rank) test was used to compare the survival curves (A and B). Two-tailed
Fisher’s exact test was used to compare the groups (C and G). Scale bars: 250 mm (D and E) and 50 mm (H).
See also Figure S2.
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rate than those in the clusters of p53D5–6/D5–6 brains (Figures 2F
and 2G). Furthermore, p53D5–6+ glioma precursor cells were
largely restricted within the SVZ of this p53D5–6/D5–6RictorD/D
brain, whereas glioma precursors were widely distributed in sur-
rounding areas of the SVZ of p53D5–6/D5–6 brains (Figures 2D, 2E,
and S2D). Loss of both Rictor alleles also significantly reduced
the proliferation rate in malignant gliomas analyzed at end
stages (Figures 2H and 2I). These results demonstrate that
Rictor/mTORC2 loss inhibits both tumor initiation and progres-
sion, thereby prolonging the survival of p53D5–6/D5–6RictorD/D
mice with malignant gliomas.
We confirmed that all malignant gliomas only expressed the
recombined p53D5–6 alleles, and both floxed Rictor alleles were
recombined in the p53D5–6/D5–6RictorD/D gliomas (Figure S2E).
Consistent with humanGBMs, almost allRictor-proficient gliomas
in p53D5–6/D5–6 and p53D5–6/D5–6Rictor+/D mice exhibited robust
expression of phosphorylated pAktS473 and pAktT308, accompa-
nied by the loss of Pten expression (Figures 2J and S2F). In
contrast, Rictor-deficient gliomas in p53D5–6/D5–6RictorD/D mice
showed little or no pAktS473 and pAktT308 expression without
altering the total level of Akt (Figure 2J). The phosphorylation of
Ndrg1 by another mTORC2 substrate, SGK1, was also signifi-
cantly reduced in Rictor-deficient gliomas compared to Rictor-
proficient gliomas (Figure 2J). These results demonstrate that
Rictor deletion almost completely abolishes the mTORC2 activity
for the phosphorylation of AktS473 andNdrg1T346/SGK1, aswell as
AktT308, a PDK1 phosphorylation site that is strongly correlated
with Akt kinase activity (Janku et al., 2018; Laplante and Sabatini,
2012). Although Rictor is not a subunit of mTORC1, decreased
mTORC1 activity was observed in most Rictor-deficient malig-
nant gliomas, as indicated by reduced phosphorylation of its
direct substrates S6KT389 and 4E-BP1T37/46 (Figure 2J). The effect
of Rictor deletion on mTORC1 is likely an indirect consequence
mediated by Akt inhibition, because Akt is known to activate
mTORC1 by the phosphorylation of Tsc2 at T1462, which was
significantly reduced in Rictor-deficient gliomas (Figure 2J) (Lap-
lante and Sabatini, 2012). Together, these results demonstrate
that Rictor deletion nearly completely inhibits mTORC2 and Akt
activity and greatly reduces mTORC1 activity in p53D5–6mutant-
driven malignant gliomas. Of note, the activation of other onco-
genic pathways, including c-Myc, Erk/MAPK, and GSKb-medi-
ated signaling pathways, was not significantly different between
Rictor-deficient and -proficient gliomas (Figures 2J and S2F).
These observations demonstrate that despite a potent inhibition
of three signaling pathways—mTORC2, Akt, and mTORC1—
Rictor deletion is not sufficient to completely eliminate p53D5–6-
mutant-driven malignant glioma formation.
Rictor Deletion Promotes p53-Mutant-Driven
Medulloblastoma Formation
Despite a robust inhibition of malignant gliomas and prolonged
survival by Rictor deletion, a subset of the p53D5–6/D5–6RictorD/D
mice developed malignant brain tumors at a rate that matched
thep53D5–6/D5–6micewith the shortest tumor latency (Figure 2A).
Almost all of the p53D5–6/D5–6RictorD/Dmice in this subset devel-
oped MBs in the hindbrain, particularly in the cerebellum (Fig-
ure 3A). All of the p53D5–6-mutant-driven MBs, including
p53D5–6/D5–6RictorD/D MBs, were characterized as large cell/
anaplastic or classic pathology with high cellular density, nu-
clear molding and Rosette structures, robust p53D5–6 expres-
sion, and occasional neuronal (synaptophysin) and glial
(GFAP) differentiation as seen in human MBs (Figure 3B) (Louis
et al., 2016). These p53D5–6-mutant-driven MBs exhibited
robust Pax6 (a granule cell lineage-specific marker in the cere-
bellum) expression with minimal levels of Olig2. Conversely,
p53D5–6-mutant-drivenmalignant gliomas expressed high levels
of Olig2 with minimal expression of Pax6 (Figures 3C–3E). This
opposite expression pattern of Pax6 and Olig2 reliably distin-
guished MBs from malignant gliomas, even when both types
of malignant brain tumors were observed in the cerebellum (Fig-
ure 3C) or in the different regions of the same brain (Figure 3D).
In contrast to p53D5–6-mutant-driven malignant gliomas, the
majority of p53D5–6-mutant-driven MBs, regardless of Rictor
status, exhibited low activities of mTORC2, Akt, and mTORC1
(Figures 3E and S3A). Furthermore, Ptch1-mutant-driven MBs,
a well-established model for SHH-MBs, also exhibited low ac-
tivities of these three signaling pathways even in the presence
of WT Rictor (Figures 3E and S3A) (Frappart et al., 2009).
More important, p53D5–6-mutant-driven MBs, not malignant gli-
omas, expressed high levels of Pax6, Gli1, and Atoh1, similar to
Ptch1 mutant-driven SHH-MBs (Figures 3E and 3F). These re-
sults demonstrate that p53D5–6-mutant MBs exhibit the critical
molecular characteristics of pediatric SHH-MBs, including low
activities of mTORC2/Akt and mTORC1 signaling pathways
(Kool et al., 2014).
We found that p53D5–6-mutant-driven MBs consistently devel-
oped more rapidly than malignant gliomas, arguing against the
possibility that the increased MB incidence by Rictor deletion
results from extended lifespan as a consequence of inhibiting
malignant gliomas (Figure S3B). Moreover, loss of one or two
alleles of Rictor on the p53D5–6/D5–6Pten+/D-double mutant back-
ground also increased the MB incidence from 17% to 48% and
79%, respectively (Figures S3D–S3G). These observations
demonstrate that Rictor deletion, not potential differences in
malignant glioma formation or genetic background, leads to a
dramatic increase in SHH-MB incidence in both p53D5–6/D5–6
and p53D5–6/D5–6Pten+/D mice.
Inhibition of Rictor/mTORC2-Dependent Akt Signaling
Promotes SHH-MB Formation via Prolonging GCP
Proliferation
We compared the gene expression profiles of the p53D5–6-
mutant-driven MBs with those of normal cerebellum; purified
granule cell precursors (GCPs, the cells-of-origin of SHH-MBs);
and mouse MBs with characteristics of SHH, WNT, and group 3
subgroups (Northcott et al., 2012). Our results showed that the
gene expression profile of p53D5–6-mutant-driven MBs was
strongly associated with SHH-MBs and similar to GCPs, but
not the group 3 and WNT MBs or normal cerebellar tissues (Fig-
ures 4A and 4B). Furthermore, all 22 p53D5–6-mutant-drivenMBs,
irrespective of Rictor genotype status, expressed high levels of
Shh-specific genes, including Gli1, Atoh1, Boc, and Sfrp1, which
were not expressed in p53D5–6-mutant-driven malignant gliomas,
the group 3 and WNT MBs, or normal cerebellar tissues (Figures
S4A–S4C). qPCR analysis further confirmed that the Shh targets,
including Gli1, Gli2, N-Myc, and Atoh1, were highly expressed in
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Figure 3. Rictor Deletion Promotes p53-Mutant-Driven Medulloblastoma Formation
(A) Scatterplot representation of malignant gliomas and MBs along with their corresponding survival rates in three GEM models.
(B) Histopathological features of the p53D5–6/D5–6RictorD/D MBs. H&E staining shows the dense tumor (i) with carrot-shaped nuclei, apoptotic cells, and nuclear
moldings (ii). Tumors were immunoreactive to p53 (iii) and synaptophysin (iv) antibodies. Tumor areas with GFAP (v) and GFAP+ (vi) are shown. Insets are higher
magnification images.
(C) Immunohistochemical analysis of Pax6 and Olig2 expression in a p53D5–6/D5–6RictorD/D MB and a p53D5–6/D5–6 malignant glioma located in the cerebellum.
Insets show higher magnification views.
(D) Pax6 and Olig2 staining in adjacent sections of a p53D5–6/D5–6RictorD/D brain with a malignant glioma in the forebrain and an MB in the cerebellum.
(E) Western blot analysis of MBs from different GEM models. WT cerebellar tissue (CTR) and two malignant glioma samples (last two lanes) are included.
SHH-MB-related markers are framed with a red dashed-line box.
(F) Immunohistochemical analysis of Atoh1 expression in MBs and malignant glioma located in the cerebellum.
Scale bars: 50 mm (B), 1 mm (C and D), and 250 mm (F).
See also Figure S3.
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p53D5–6-mutant-driven MBs at comparable levels to the Ptch1
mutant-driven SHH-MBs (Figure 4C). These results demonstrate
that Rictor/mTORC2 loss significantly increases the incidence of
SHH-MBs on the p53D5–6-mutant background.
Rictor/mTORC2 loss does not significantly alter the latency or
type of MBs on the p53D5–6-mutant background (Figure 3A).
Thus, we hypothesize that the increased incidence of SHH-
MBs in p53D5–6/D5–6RictorD/D mice results from the growth-pro-
moting effects of GCPs, which constitute the external granular
layer (EGL), a structure only transiently present in the developing
cerebellum (Northcott et al., 2012). At postnatal day 16 (P16),
both Pax6+ and proliferating Pax6+BrdU+ GCPs were readily
identified in each folium of Rictor-deficient cerebella (regardless
of p53mutational status), whereas almost noGCPswere present
in most folia of control cerebella, accompanied by the disap-
pearance of the EGL (Figures 4D–4F). Overall, the EGL of
Rictor-deficient cerebella exhibited a 3-fold and 2-fold of in-
crease in the cellular density and total number of proliferating
GCPs, respectively (Figures 4G, S4D, and S4E).
To determine the cellular mechanism by which Rictor deletion
promotes sustained proliferation of GCPs, we performed a BrdU
pulse-chase assay to investigate cell-cycle exit of GCPs in
Rictor-deficient versus Rictor-proficient cerebella from P15 to
P17. Consistent with the observations at P16, only a small num-
ber of BrdU+ cells labeled at P15 were still detected at P17 in
most of the control folia, most of which exited the cell cycle
and migrated out of the EGL into the molecular layer (ML) or
the internal granular layer (IGL) (Figures 4H and 4I). In contrast,
the number of P15-labeled BrdU+ cells was dramatically
increased in P17 Rictor-deficient cerebella, which was mainly
caused by the cells sustained in the EGL, including proliferating
BrdU+Ki67+ GCPs (Figures 4H, 4I, and S4F). When cerebellar
development was complete at P22, Rictor-deficient cerebella
exhibited ectopic accumulation of Pax6+ cells in the ‘‘persistent’’
EGL (Figures S4G–S4J). More important, abnormally prolifer-
ating Pax6+ GCPs were observed only in Rictor-deficient cere-
bella, particularly in folium 10b (Figures S4K and S4L). Together,
these results are most consistent with a model wherein Rictor
deletion delays timely differentiation of a subset of GCPs, pro-
longing their proliferation in the EGL.
Pharmacological Inhibition of Akt Signaling Delays GCP
Differentiation via Stabilizing Atoh1 Protein
We investigated the molecular mechanism by which Rictor/
mTORC2 loss leads to the delay in timely differentiation of
GCPs during cerebellar development. First, we determined
Rictor/mTORC2 activity during GCP development using the
expression of pAktS473. At the peak of migration of differentiating
GCPs in P8 cerebella, almost no pAktS473 activity was observed
in the EGL, while robust pAktS473 expression was found in the
ML, and many differentiated neurons were found in the IGL (Fig-
ure 5A). Despite high levels of pAktS473 expressed in cell bodies
and fibers of GFAP+ Bergmann glial cells, a subset of migrating
GCPs with high pAktS473 expression was identified in the ML
(Figures 5A and S5A). When pAktS473 expression became
restricted to cell bodies of Bergmann glial cells at P11, a subset
of migrating GCPs with high levels of pAktS473 was readily iden-
tified in the ML (Figure 5B). More important, differentiated
granule neurons in the IGL were the only cells with detectable
pAktS473 expression in the adult cerebellum (Figure S5B). These
results demonstrate that high levels of mTORC2/Akt activity are
associated with differentiated cells in the granule cell lineage,
including a subset of migrating and differentiating GCPs in the
ML, and granule neurons in the IGL, but not in undifferentiated
GCPs in the EGL.
Second, we sought to determine whether mTORC2-depen-
dent Akt signaling is required for GCP differentiation. We there-
fore treated WT mice from P8 to P16 with BKM120, one of the
most extensively tested pan-PI3K/AKT inhibitors in clinical trials
(Janku et al., 2018). BKM120 treatment led to a reduction in the
weight of the brain, mimicking the postnatal phenotypes
observed in Rictor-deficient mice (Figures S5C–S5E and S5F–
S5H). BKM120 treatment caused an increased number of prolif-
erating GCPs in the EGL of multiple folia, thus recapitulating
abnormally sustained proliferation of Rictor-deficient GCPs (Fig-
ures 5C–5E, S5I, and S5J). Similar to Rictor-deficient cerebella,
an abnormal accumulation of GCPs was observed in the EGL
of multiple folia of the BKM120-treated cerebella (arrowheads
in Figures 5F, S5K, and S5L). BKM120 treatment increased the
number of GCPs with expression of Atoh1, a transcription factor
that is exclusively expressed in proliferating GCPs in the outer
Figure 4. Rictor Deletion Promotes SHH-MB Formation by Prolonging the Proliferation of Granule Cell Precursors
(A and B) Microarray analysis of genome-wide expression profiles of the p53-mutant-drivenMBs in comparison with normal cerebellum and previously published
GEMmodels of WNT, SHH, and group 3MBs. An area containing the genes specifically upregulated in the SHH-MBs and GCPs is highlighted with the horizontal
white box (A). The genes in this area are listed in (B) and the important ones are highlighted in yellow.
(C) qPCR experiments were performed using cDNAs from p53D5–6-driven MBs in comparison with the Ptch1+/models. Two malignant glioma samples and one
P13 normal cerebellar tissue were used as negative controls.
(D–G) Control and mutant mice at P16 were injected with BrdU and analyzed 2 hr later. The overall cerebellar structure along with the Pax6+ cells and BrdU+
proliferating cells were examined. Each folium (‘‘F’’) is labeled with Roman numerals (D). White frames indicate three areas (F-5/6, F-9/10a, and F-10b) that were
subjected to further analysis. Two types of Rictor mutant mice are highlighted by red dashed-line boxes. Higher magnification of F-9/10a regions in (D), and
corresponding H&E staining is shown (E). Pax6+ cells and proliferating BrdU+Pax6+ cells in the EGL-associated areas were quantified in three folia of P16 control
and mutant cerebella (F). The total number of BrdU+ proliferating cells per unit area (mm2) was calculated for control and mutant cerebella individually (G).
(H and I) Cell-cycle analysis was performed by injecting the mice with BrdU once at P15 and analyzing at P17. Two types of Rictormutant mice are highlighted by
red dashed-line boxes. (H) The cells proliferating at P15 were labeled with BrdU upon injection. Those subsequently exiting the cell cycle at P17 were labeled
BrdU+Ki67 (green), and those remained or re-entered cell cycle were labeled BrdU+Ki67+ (yellow). Higher magnification view of the EGL cells in F-5/6, F-9/10a,
and F-10b are shown. (I) The number of BrdU+ cells in EGL,ML, and IGL are quantified. The distribution of each type of BrdU+ cells is shownwith bar graphs. The p
values for the comparisons of BrdU+Ki67+ cells in EGL (yellow bars) are shown. Additional comparisons are listed in Figure S4F.
All of the quantification data are presented as means ± SEMs. Unpaired Student’s t test was used to compare the groups statistically. Scale bars: 1 mm (D),
100 mm (E), and 250 mm (H). EGL, external granular layer; IGL, internal granular layer; ML, molecular layer.
See also Figure S4.
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EGL (Figures 5G and 5H). Given that Atoh1 is required for main-
taining an undifferentiated state of proliferating GCPs (Ayrault
et al., 2010), these results raise the possibility that genetic and
pharmacological inhibition of Akt signaling leads to increased
Atoh1 expression, delaying timely differentiation of GCPs and
prolonging their proliferation.
Third, we established and screened early-passage p53D5–6-
mutant-driven MB cell lines that maintained high levels of
Atoh1 expression of their primary tumors, allowing us to investi-
gate the regulation of endogenous Atoh1 protein (Figures 3E and
3F). In contrast to DMSO-treated cells, BKM120 treatment
inhibited Akt activation and promoted accumulation of Atoh1
protein in a dose-dependent manner. At a low dose of 0.1 mM,
BKM120 greatly inhibited Akt activation without inducing
apoptosis (Figure 5I). Of note, a higher concentration at
0.5 mM, despite further inhibiting Akt activity, induced apoptosis
at later time points. More important, BKM120-mediated accu-
mulation of Atoh1 protein was observed in a time-dependent
Figure 5. Pharmacological Inhibition of Akt Signaling Delays Granule Cell Precursor Differentiation by Blocking Atoh1 Degradation
(A and B) pAktS473 immunohistochemical staining inWT and p53+/D5–6RictorD/D cerebella at P8 (A) and inWT at P11 (B). Arrows indicate the differentiated neurons
with robust pAktS473 expression in IGL. Arrowheads indicate the migrating granule cells with high pAktS473 expression in ML.
(C–H)WTmice were treated with vehicle or BKM120 (10 mM) fromP8 to P16. Analyses were performed at P16. (C) Representative images of cerebellar sections in
vehicle- or BKM120-treated WT mice. BrdU and Ki67 staining are shown in grayscale; DAPI is shown in blue. F-6 and F-7 are indicated with Roman numerals.
(D and E) Total BrdU+ cell number was quantified in the entire EGL (D) or only in F-6 and F-7 (E) of the treated mice. (F) Representative H&E staining of cerebella
from vehicle- or BKM120-treated mice. Higher magnification images of marked areas in F-6a/-6b are shown. Arrowheads indicate the retained cells in EGL.
(G and H) Atoh1 and Ki67 staining in adjacent sections of vehicle- and BKM120-treated WT cerebella. F-6 is shown. Areas outlined in red dashed lines are shown
in higher magnifications in (H). Arrowheads point toward Atoh1+ cells.
(I–L) p53D5–6/D5–6 medulloblastoma cell line was treated as indicated, and cells were collected and subjected to western blot analysis. (I) Cells were treated with
DMSO or different doses of BKM120 as indicated for 24 hr. The band density of Atoh1 was quantified and the ratio of Atoh1/b-actin was calculated. (J and K) Cells
were treated with BKM120 (0.1 mM [J]) or MG132 (10 mM [K]), as indicated. (L) Cells were treated with 200 mg/mL cycloheximide (CHX) together with DMSO,
BKM120, or MLN4924, as indicated. One representative result (of four) is shown.
(M) The band density of Atoh1 and b-actin were quantified for each repeated experiment in (L). The percent ratio of Atoh1/b-actin was calculated accordingly and
graphed. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.
All of the quantification data are presented as means ± SEMs. Unpaired Student’s t test was used to compare the groups in (D) and (E). Two-way ANOVA was
performed in (M). Scale bars: 100 mm (A and B), 250 mm (C), and 50 mm (F–H). EGL, external granular layer; IGL, internal granular layer; ML, molecular layer.
See also Figure S5.
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manner (Figure 5J). During the 24-hr treatment period, no signif-
icant difference in the number of cells or transcription of Atoh1
mRNAs was observed (Figures S5M and S5N). Therefore, it is
unlikely that BKM120 promotes the accumulation of Atoh1 pro-
tein via increasing cell numbers or Atoh1 transcription. Instead,
MG132, a proteasome inhibitor, also promoted the accumulation
of Atoh1 protein in a time-dependent manner similar to BKM120,
raising the possibility that Akt inhibition stabilizes Atoh1 protein
by blocking ubiquitin-proteasome-mediated protein degrada-
tion (Figure 5K). We therefore measured the half-life of Atoh1
protein in MB cells treated with BKM120 or MLN4924 for 4, 8,
12, 16, and 24 hr in the presence of cycloheximide (CHX), which
blocks new protein synthesis. MLN4924, a neddylation inhibitor
of Cullin-RING E3 ubiquitin ligases (CRLs), blocks protein degra-
dation by inhibiting neddylation of the Cullin protein of CRLs
(Soucy et al., 2009). Both BKM120 and MLN4924 treatment
significantly prolonged the half-life of Atoh1 protein from
4.56 hr in the DMSO-treated group, to 12.82 hr in the
BKM120-treated group, and to 21.26 hr in the MLN4924-treated
group (Figures 5L and 5M). BKM120-mediated Akt inhibition in-
creases the half-life of Atoh1 protein, demonstrating that Akt
signaling negatively regulates the protein stability of Atoh1,
possibly by promoting CRL-mediated ubiquitylation and degra-
dation. These results provide a molecular mechanism by which
the inhibition of the mTORC2/Akt signaling pathway delays
timely differentiation of GCPs and prolongs their proliferation.
p53-Mutant-Driven SHH-MBs Share Critical Features of
TP53Mutant SHH-MBs in Humans
The persistent proliferation of Rictor-deficient GCPs exclusively
observed on the p53D5–6/D5–6 background suggests a p53-
dependent cellular response or responses that drive the cell-cy-
cle exit of abnormally proliferating Rictor-deficient Pax6+ GCPs
at the late stages of cerebellar development (Figures S6A–
S6C). This tumor-suppressive response explains that Rictor/
mTORC2 loss did not induce SHH-MBs on the p53+/+ or
p53+/D5–6 background. The activation of p53-mediated re-
sponses inRictor-deficient GCPs was consistent with the obser-
vation that p53D5–6+ cells were readily identified in multiple folia
of the p53D5–6/D5–6RictorD/D, but not p53D5–6/D5–6 cerebella at
P22 (Figures 6A and 6B). Many p53D5–6/D5–6RictorD/D cerebella
(4/7) but not p53D5–6/D5–6 cerebella (n = 6) contained clusters of
p53D5–6+ cells at P60, some of which were proliferating, reminis-
cent of MB precursor cells (Figures 6C and S6D). It is important
to note that the percentage of proliferating cells expressing
p53D5–6 (BrdU+p53+/BrdU+) almost reached 80%–100% at P60
compared to 10%–20% in GCPs at P16, suggesting clonal se-
lection from p53D5–6+ GCPs during postnatal development to
MB precursor cells in young adult cerebella (Figures 6C and
S6A–S6C). Thus, Rictor/mTORC2 loss expands and prolongs
the GCP population that is susceptible to p53D5–6-mutant-driven
SHH-MB formation during postnatal cerebellar development.
Although virtually all p53-deficient SHH-MBs of previously
published mouse models harbor biallelic inactivation of Ptch1
(Frappart et al., 2009), TP53 mutant SHH-MBs in humans infre-
quently carry PTCH1 mutations and have at least one normal
PTCH1 allele (Kool et al., 2014; Northcott et al., 2012). We per-
formed qPCR, targeted deep sequencing of the Ptch1 gene
(3003), and low-coverage whole-genome sequencing
(103), demonstrating that a significant number of p53D5–6-
mutant-driven SHH-MBs, regardless of Rictor status, retained
at least one WT allele of Ptch1 (Figure 6D, marked by *, and
S6E). In particular,70%ofRictor-deficient SHH-MBs exhibited
eitherWT or heterozygous Ptch1, with a high frequency of ampli-
fication ofN-Myc and/orGli2, the critical features of human TP53
mutant SHH-MBs (Figures 6E, 6F, and S6F). In contrast, almost
all Ptch1 mutant-driven MBs analyzed in this study (>90%, n =
32) harbored biallelic Ptch1 inactivation (via loss of Ptch1 WT
allele) (Figures 6D and S6E). Moreover, p53D5–6-mutant-driven
SHH-MBs also exhibited other critical genomic features of hu-
man TP53 mutant SHH-MBs, including heterozygous loss of
chr10q/PTEN and chromosomal abnormalities such as tetra-
ploidy, harboring four times the haploid number of chromo-
somes (Figures S6G–S6M, S7A, and S7B) (Kool et al., 2014).
These results demonstrate that Rictor deletion promotes
p53D5–6-mutant-driven SHH-MBs, which recapitulate the critical
histopathological, molecular, genetic, and genomic features of
TP53mutant SHH-MBs in humans. In summary, these observa-
tions demonstrate that Rictor deletion promotes the rapid
generation of p53D5–6+ MB precursor cells from GCPs in the
EGL during late stages of cerebellar development, while delaying
the emergence of p53D5–6+ glioma precursor cells from the SVZ
stem cell niche of the adult brain (Figure S7C).
Impact of RICTOR Expression in Pediatric SHH-MBs and
Adult GBMs in Humans
Despite high levels of similarity between mouse p53D5–6-mutant
SHH-MBs and human TP53 mutant SHH-MBs, no homozygous
deletion of RICTOR was identified in human SHH-MBs (Kool
et al., 2014). We therefore used a bioinformatics approach to
divide pediatric SHH-MBs into ‘‘RICTOR-high’’ and ‘‘RICTOR-
low’’ groups based on mRNA expression data (see STAR
Methods). The SHH-MBs within the RICTOR-low group were
associated with poor survival among pediatric SHH-MBs (Fig-
ures 7A and 7B). TP53 mutant SHH-MBs are one of the two
MB subgroups with the worst survival rates and are responsible
for the majority of the mortality associated with SHH-MBs (Kool
et al., 2014; Northcott et al., 2012). The majority of TP53 mutant
SHH-MBs (65%) were consistently observed in the group, with
the lowest RICTOR expression found among SHH-MBs (Figures
7A and 7B). Thus, the poor survival of theRICTOR-low group is at
least partially contributed to by an enrichment of TP53 mutant
SHH-MBs. Among TP53-WT SHH-MBs, more pediatric patients
with lower levels ofRICTOR expression died during the follow-up
studies (Figures 7C and 7D). These results suggest that low
levels of RICTOR expression may negatively affect patient sur-
vival independent of its association with TP53 mutations,
although a large number of patients with SHH-MBs are needed
to validate this observation.
Given that the mTORC2-dependent AKT signaling is the ma-
jor downstream effect of the PI3K/PTEN pathway, we further
determined the frequency of mutational events in the PI3K/
AKT pathway in SHH-MBs and compared them to adult primary
GBMs,most of which exhibit genetic alterations in the PI3K/AKT
pathway (Brennan et al., 2013). Approximately 32% of infant,
39% of childhood, and 16% of adult SHH-MBs exhibited the
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Figure 6. p53-Mutant-Driven MBs Share Critical Features of TP53 Mutant SHH-MBs in Humans
(A) Proliferating p53D5–6+ cells in multiple folia in p53D5–6/D5–6RictorD/D cerebella at P22. NeuN staining labels the differentiated IGL cells.
(B) The total number of p53D5–6+ cells in three different folia from P22 WT and mutant mice is shown.
(C) Clustered BrdU+p53D5–6+ cells in p53D5–6/D5–6RictorD/D cerebella at P60. Arrows indicate BrdU+p53D5–6+ cells; arrowheads indicate BrdU+p53 cells.
(D) SHH pathway alterations in SHH-MBs from different GEM models.
(E) Analysis of CNAs inN-Myc andGli2 genes in a bigger pool of MB samples. Copy-number ratiosR1.25 were considered low-level amplifications/gains (orange
area), ratios >2 were considered high-level amplifications (light red area).
(F) Amplified chromosomal regions containing N-Myc and Gli2 genes (red) detected by low-coverage whole-genome sequencing (lcWGS). This parameter is
shown as a ratio of tumor versus control tissue. Baseline is shown with a red line across the plots.
Scale bars: 50 mm (A and C). EGL, external granular layer; IGL, internal granular layer; ML, molecular layer.
See also Figures S6 and S7.
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Figure 7. RICTOR Expression Is Correlated with Opposite Clinical Outcomes in Adult GBMs and Pediatric SHH-MBs
(A–D) Scatterplot distribution of RICTOR gene expression among all pediatric SHH-MBs (A) or pediatric SHH-MBs with WT TP53 only (C). Patients who suc-
cumbed to the disease are indicated with red dots, while the survivors at the time of analysis are shown with green dots. The survival analysis for both groups is
shown in (B) and (D). Tumors with detected TP53 mutations are indicated with asterisks in (B).
(E) Distribution of TP53, PTEN, and PIK3CA gene mutations and chr10q loss in SHH-MBs among the three age subgroups.
(F) The frequencies of 10q loss, biallelic PTEN inactivation, and pAKT positivity (* derived from two previous studies) are compared between adult primary GBMs
and SHH-MBs.
(legend continued on next page)
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loss of one copy of chr10q/PTEN (heterozygous loss) (Figures
7E and 7F). In contrast, nearly all IDH-WT GBMs (97% of 221
cases in The Cancer Genome Atlas [TCGA] database) exhibited
chr10q/PTEN loss (Figure 7F) (Brennan et al., 2013). More
important, biallelic inactivation of PTEN caused by homozygous
deletions or additional loss-of-function mutations in the second
alleles was observed in 41% of adult primary GBMs, which
rarely occurred in infant (6%) and adult SHH-MBs (4%) and
none in childhood SHH-MBs (0%), the age group that harbors
the most TP53 mutations (Figures 7F and 7G). Genetic alter-
ations in the PIK3CA were also rare in pediatric SHH-MBs
(infant, 6% and childhood, 0%) (Figure 7E). Together, high
versus low frequency of genomic and molecular alterations
in the PI3K/AKT signaling pathway in human adult primary
GBMs versus pediatric SHH-MBs are consistent with the
opposing tumor-promoting versus tumor-suppressing effects
of Rictor/mTORC2-dependent Akt signaling observed in our
mouse studies. In support, adult IDH-WT/non-G-CIMP GBMs
with high levels of RICTOR mRNA expression were associated
with poor survival, particularly for the patients surviving
>7 months (Figures 7H–7J). RICTOR is the only component of
mTORC2 or mTORC1 whose mRNA expression level has an
opposite relation to survival of pediatric SHH-MBs and adult
GBMs (Figure S8).
DISCUSSION
The unique aspect of the conditional p53D5–6 brain tumor model
is that the driving p53D5–6 mutation itself does not directly pro-
vide growth advantage but instead allows spontaneous accumu-
lation of oncogenic alterations in targeted cells, which in turn
drive malignant transformation. Despite the p53D5–6 mutation
being conditionally targeted toward embryonic neural stem cells
and mature astrocytes, no tumor in the brain was observed until
late adulthood (6–12 months) (Figure 3A) (Wang et al., 2009,
2012). The cell- or cells-of-origin of these p53D5–6-mutant-driven
brain tumors must be the cells with self-renewing potentials
(e.g., neural stem and progenitor cells) that can undergo multiple
cell divisions, allowing spontaneous accumulation of oncogenic
alterations sufficient for malignant transformation (Ihrie and Al-
varez-Buylla, 2011; Northcott et al., 2012). Thus, the conditional
p53D5–6 brain tumor model provides an experimental system
with which to discover and validate oncogenic drivers that accu-
mulate in neural stem and progenitor cell populations, which
would directly confer growth advantage during the initiation
and progression of p53D5–6-mutant-driven malignant gliomas
and SHH-MBs.
The vast majority of p53D5–6-mutant mice acquire chr19/Pten
loss during malignant glioma formation. The presence of addi-
tional Pten+/ mutation on the p53D5–6-mutant background cir-
cumvents chr19/Pten loss, which is also absent in GFAP-creER
(estrogen receptor)-driven p53/Pten-double or p53/Pten/Rb-
triple mutant models (Chow et al., 2011). These observations
suggest that the major target of chr19 loss is the Pten tumor-
suppressor gene, which consequently activates the PI3K/Akt
signaling pathway in this glioma model. Rictor/mTORC2 loss
consistently inhibits Akt signaling, thereby reducing the inci-
dence and delaying the formation of malignant gliomas and
GBMs in both p53D5–6-mutant and p53D5–6/Pten+/-double
mutant-driven models. Recent studies using human GBM cells
have demonstrated that RICTOR/mTORC2 integrates intracel-
lular growth factor receptor signaling with extracellular nutrient
availability, reprogramming cancer metabolism and causing
drug resistance of PI3K/AKT/mTOR inhibitors (Masui et al.,
2013, 2015; Wu et al., 2014). The availability of GEM Rictor-
proficient and Rictor-deficient malignant gliomas and GBMs
provides an in vivo experimental system with an immunocompe-
tent environment in which to investigate Akt-dependent and Akt-
independent mechanisms of mTORC2 in reprogramming GBM
metabolism. Furthermore, preclinical studies will be performed
to target metabolic vulnerability caused by mTORC2 inhibition
in these GEM models. Despite the potent inhibition of mTORC1,
mTORC2, and Akt signaling pathways, it should be noted that
the emergence of Rictor-deficient gliomas highlights the utility
of this glioma model to investigate therapeutic resistance to
PI3K/AKT/mTOR inhibitors.
We have identified a novel tumor-suppressive function of
Rictor/mTORC2 in the pathogenesis of p53D5–6-mutant-driven
SHH-MBs. It has been well documented that neural stem cells
in the SVZ stem cell niche remain undifferentiated throughout
the lifespan, providing the opportunity for p53D5–6-mutant cells
to accumulate oncogenic alterations that are sufficient for malig-
nant glioma/GBM formation (Ihrie and Alvarez-Buylla, 2011;
Wang et al., 2009; Zhu et al., 2005). However, GCPs are a tran-
sient precursor population during cerebellar development, which
must accumulate oncogenic alterations during a limited devel-
opmental window to generate MB precursors (Northcott et al.,
2012). Mechanistically, Rictor deletion causes a delay in timely
differentiation of a subset of GCPs, whose differentiation is asso-
ciated with the activation of mTORC2/Akt signaling. Conse-
quently, these Rictor-deficient GCPs abnormally continue to
proliferate in the persistent EGL. The sustained proliferating
GCPs therefore increase the population size for tumor-suscepti-
ble cells to accumulate oncogenic alterations (e.g., Gli2 and/or
N-Myc amplification), leading to increased SHH-MB penetrance
on the p53D5–6-mutant background. These observations suggest
that the shift of the tumor spectrum from malignant gliomas to
SHH-MBs results from the opposing role of Rictor/mTORC2 in
neural stem cells in the adult SVZ versus GCPs in the EGL in
the postnatal developing cerebellum (Figure S7C).
(G) Percentages of TP53 mutations within each age subgroup of SHH-MBs.
(H) Scatterplot representation of RICTOR expression among human primary GBM samples.
(I and J) Overall survival probability of the GBM patients based on their RICTOR expression. The whole cohort is shown in (I); patients with survival >7 months are
shown in (J).
Multiple corrected log-rank tests between pairs of groups are used for comparisons of survival curves in (B), (D), (I), and (J). The individual datasets are initially
scanned to find the cutoff in expression that results in the lowest p value between high and low expression values.
See also Figure S8.
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Pharmacological inhibition of the PI3K/Akt signaling
pathway during postnatal cerebellar development blocks
GCP differentiation and increases the sustained proliferating
GCP population during postnatal cerebellar development
(Dimitrova and Arcaro, 2015). Thus, the effects of this PI3K/
AKT inhibitor treatment partially mimic the delayed differentia-
tion and sustained proliferation of GCPs observed in Rictor-
deficient cerebella. Along with the observation that highly
phosphorylated AktSer473 is associated with the differentiation
of GCPs, these results demonstrate a critical role for Rictor/
mTORC2-dependent Akt signaling in promoting differentiation
of a subset of GCPs and suppressing SHH-MB formation.
Increased numbers of GCPs with Atoh1 expression observed
in BKM120-treated cerebella suggest a mechanistic basis of
the negative role of Rictor/mTORC2/Akt signaling in GCP
proliferation. We provide direct evidence that Akt inhibition
promotes the accumulation of Atoh1 protein, possibly via
blocking CRL-mediated protein degradation. These results
provide a molecular mechanism for a recent clinical observa-
tion that no or low levels of AKT or mTORC1 activity are de-
tected in most pediatric SHH-MBs (Kool et al., 2014). We
also observed low AKT activation in 5 human MB-derived
cell lines (3 SHH-MB lines and 2 group 3/4 lines), which are
more resistant to a PI3K/AKT inhibitor compared to GBM
cell lines (S.A., unpublished data). It will be important to vali-
date the tumor-suppressive functions of mTORC2/AKT
signaling in patient-derived cell lines and xenograft models
of MBs. Thus, our study suggests that caution should be taken
in the design of clinical trials using PI3K/AKT/mTOR inhibitors
to treat brain tumors in children (Dimitrova and Arcaro, 2015;
Janku et al., 2018).
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REAGENT or RESOURCE SOURCE IDENTIFIER
Antibodies
Rabbit anti-p53 Leica P53-CM5P-L
Rabbit anti-Olig2 Millipore AB9610
Rabbit anti-GFAP Dako Z0334
Rabbit anti-Synaptophysin Covance MMS-618R
Rabbit anti-Pax6 Covance PRB-278p
Rabbit anti-Ki67 Abcam ab15580
Rabbit anti-pAktS473 Cell Signaling 4060L
Rabbit anti-Atoh1 Dr. Jane Johnson from
UT Southwestern
N/A
Mouse anti-Atoh1 Abcam ab27667
Mouse anti-Atoh1 Developmental Studies
Hybridoma Bank
N/A
Rat anti-BrdU Abcam ab6326
Mouse anti-Ascl1/Mash1 BD PharMingen 556604
Mouse anti-Nestin Millipore MAB353
Goat anti-Sox2 Santa Cruz Biotech sc-17320
Mouse anti-Calbindin Sigma-Aldrich C9848
Mouse anti-NeuN Millipore MAB377
Alexa Fluor 488 Invitrogen, Life Technologies A11004; A11034
Alexa Fluor 555 Invitrogen, Life Technologies A21429; A21424
Alexa Fluor 647 Invitrogen, Life Technologies A31571; A21236; A21247; A21245
Alexa Fluor 555-conjugated streptavidin Thermo Fisher Scientific S-32355
Rabbit anti-pAktT308 Cell Signaling 2965S
Rabbit anti-Akt Cell Signaling 9272S
Rabbit anti-pNDRG1T346 Cell Signaling 5482S
Rabbit anti-Pten Cell Signaling 9559S
Rabbit anti-Rictor Dr. D. Fingar from University
of Michigan
N/A
Rabbit anti-mTOR Cell Signaling 2983S
Mouse anti-b-Actin Sigma-Aldrich A5316
Rabbit anti-pS6KT389 Cell Signaling 9234S
Rabbit anti-p4E-BP1T37/46 Cell Signaling 9459S
Rabbit anti-pTSC2T1462 Cell Signaling 8350S
Rabbit anti-pS6S240/244 Cell Signaling 5364S
Rabbit anti-S6 Cell Signaling 2217S
Rabbit anti-cMyc Cell Signaling 5605S
Rabbit anti-pErk1/2T202/Ty204 Cell Signaling 9101S
Rabbit anti-Erk1/2 Cell Signaling 9102L
Rabbit anti-pGSK-3bS9 Cell Signaling 5558S
Mouse anti-P120 BD Biosciences 610040
Rabbit anti-Gli1 Cell Signaling 2534S
Rabbit anti-Atoh1 Abcam ab168374
Cleaved-Caspase3 Cell Signaling 9661S
Mouse anti-Cul-1 Santa Cruz sc-17775
(Continued on next page)
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CONTACT FOR REAGENT AND RESOURCE SHARING
Further information and requests for reagents should be directed to the Lead Contact Yuan Zhu (yzhu@childrensnational.org).
EXPERIMENTAL MODEL AND SUBJECT DETAILS
The mutant mice used in this study had various genotypic configurations: For brain tumor formation, hGFAP-cre;p53flox/flox, hGFAP-
cre;p53flox/flox;Rictorflox/+, and hGFAP-cre;p53flox/flox;Rictorflox/flox mice were used. A second group of mice as a validation cohort
carried additional heterozygous Ptenflox/+ mutation. Brain tumors from a group of Ptch1+/ mice with the genotype of hGFAP-
cre;Ptch1+/ and hGFAP-cre;p53flox/flox;Ptch1+/; were used as SHH-MB controls. For developmental biology studies, we utilized
a non-tumorigenic mutant mouse model with the genotype of hGFAP-cre;p53flox/+;Rictorflox/flox. The control group was a collection
of hGFAP-cre(negative) mice that were phenotypically indistinguishable and completely healthy. Age and littermate-matched control
and mutant mice were used for the developmental analyses to minimize the impact of modifier genes. Brain tumor mice were either
littermates or close relatives collected over approximately 9 years. All mice except for the original Ptch1+/ allele that contained the
FVB background were maintained in the mixed backgrounds of C57Bl6 and 129S1/Svj. The phenotypes of both malignant gliomas/
GBMs and SHH-MBs were similarly observed in male and female mice. Consequently, similar numbers of mice with both genders
Continued
REAGENT or RESOURCE SOURCE IDENTIFIER
HRP-conjugated secondary antibodies BioRad 1706515; 1706516
Chemicals, Peptides, and Recombinant Proteins
BKM120 Selleckchem S2247
Vehicle Sigma-Aldrich C5135
PEG400 Sigma-Aldrich 202398
KaryoMAX Colcemid solution GIBCO, Life Technologies 15212012
KaryoMAX Potassium Chloride Solution GIBCO, Life Technologies 10575-090
Cycloheximide Sigma-Aldrich C7698-1G
MLN4924 Selleckchem S7109
MG132 Selleckchem S2619
Critical Commercial Assays
CellTiter-Glo Luminescent Cell Viability Assay Promega G7572
QuantiTect Reverse Transcription Kit QIAGEN 205313
AllPrep DNA/RNA Mini Kit QIAGEN 80204
SYBR Select Master Mix Thermo Fisher Scientific 4472908
Deposited Data
Gene expression GEO GSE78895
Experimental Models: Cell Lines
Established primary brain tumor cell lines
from GEM models in this study
This paper N/A
Experimental Models: Organisms/Strains
hGFAP-cre Wang et al., 2009 N/A
p53E5-6flox Wang et al., 2009 N/A
Rictorflox Magee et al., 2012 N/A
Ptenflox Zheng et al., 2008 N/A
Ptch1+/ Frappart et al., 2009 N/A
Oligonucleotides
Primers for genotyping PCR, gene expression
and copy number analysis, see Table S2
This paper N/A
Software and Algorithms
GISTIC Mermel et al., 2011 https://software.broadinstitute.org/software/cprg/?q=node/31
Integrative Genomics Viewer (IGV) N/A https://software.broadinstitute.org/software/igv/
ImageJ (Version 1.52c) N/A https://imagej.nih.gov/ij/
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were used for the experiments. Mice were cared for according to the guidelines that were approved by the Animal Care and Use
Committees of the University of Michigan at Ann Arbor and Children’s National Medical Center, Washington, DC.
METHODS DETAILS
Genotyping and PCR
Taq 2X MeanGreen Master Mix (Empirical Bioscience) was used in PCR experiments along with the following primer sets for tail and
tumor tissue genotyping. See primer information in Table S2.
Tissue Preparation, Histopathology and Tumor Diagnosis
Approximately 65%–70% of the mice were sacrificed due to observable neurological symptoms including enlarged head, tremor,
seizure, ataxia, or lack of balance indicating the presence of an end-stage brain tumor. One set of these mice were perfused using
4% paraformaldehyde (PFA), brains were collected and kept in 4% PFA for at least one day. The second set of mice were sacrificed
using cervical dislocation procedure after anesthesia with 3.5% Tribromoethanol (Avertin). The brains were collected at 4C, rinsed in
4C PBS and cut sagittally along the midline. One half of the brain was kept in 4% PFA while the other half was used for frozen tissue
collection, snap freezing in liquid nitrogen, and cell culture preparation. Processed and paraffin embedded brain samples were
sectioned sagittally at 5 mm and collected on Superfrost Plus microscope slides (Fisher Scientific). Hematoxylin and eosin (H&E)
staining was performed approximately every 10 slides and adjacent sections were subjected to immunohistochemical analysis using
the antibodies for p53, Olig2, GFAP, Synaptophysin and Pax6. Samples were analyzed under a light microscope by two investigators
(SCP and SA) based upon the World Health Organization (WHO) criteria of the classification of tumors in the CNS (Louis et al., 2016).
Diagnosed high-grade malignant gliomas included anaplastic astrocytoma, glioblastoma, anaplastic oligoastrocytoma and
anaplastic oligodendroglioma. Final diagnoses were reached as a consensus of H&E staining findings and immunohistochemical an-
alyses. In rare cases where a clear diagnosis was hard to reach, Olig2 and Pax6 immunohistochemistry staining (described below)
were taken as conclusive criteria as Olig2 is characteristic of high-grade malignant gliomas whereas Pax6 labels medulloblastomas.
Immunohistochemistry and Immunofluorescence
Adjacent paraffin sections were used in immunohistochemistry and immunofluorescence analyses. Slides were first deparaffinized
through a series of Xylene, Ethanol and PBS treatments, boiled in Retrieve-All antigen unmasking system (Covance), permeabilized in
0.3% Triton X-100 (Sigma-Aldrich) and blocked with 5% normal goat serum or normal donkey serum prior to overnight primary anti-
body incubation at 4C. The visualization of the primary antibodies in immunohistochemistry was performed with the avidin/biotin-
based peroxidase system (Vectastain Elite ABC System, Vector Laboratories), except for pAktS473 and Pten, for which SignalStain
Boost IHC Detection Reagent HRP-rabbit (Cell Signaling) was used. The dilutions of the primary antibodies used on paraffin sections
in immunohistochemistry study were: p53 (1:500, rabbit, Leica), Olig2 (1:2,000, rabbit, Millipore), GFAP (1:1,000, rabbit, Dako),
Synaptophysin (1:200, rabbit, Covance), Pax6 (1:500, rabbit, Covance), Ki67 (1:500, rabbit, Abcam), pAktS473 (1:200, rabbit, Cell
Signaling), Pten (1:400, rabbit, Cell Signaling) and Atoh1 (1:500, rabbit, gift from Dr. Jane Johnson from UT Southwestern). Hema-
toxylin was used as a counterstain to label cell nuclei. Sections were examined under a light microscope (Olympus BX51 and BX53).
For Atoh1 IHC on paraffin sections, we tested three different Atoh1 antibodies: two mouse antibodies from Abcam (Ab27667) and
DSHB (Atoh1 concentrate) and one rabbit antibody (gift fromDr. Jane Johnson fromUTSouthwestern). Only the rabbit Atoh1 antibody
gives the strongest and robust staining on SHH-MBs paraffin sections with small modifications of the IHC protocol mentioned above.
For the DAB reaction step, we put the tissue slides on ice to slow down the reaction and reduce some background staining. The fresh-
ness of tissue samples has big impact on the Atoh1 staining,with high staining inmore fresh samples.WeperformedAtoh1 IHCon total
46 SHH-MBs including p53D5-6/D5-6Ptch+/ (n = 4); p53D5-6/D5-6 (n = 3), p53D5-6/D5-6Rictor+/D (n = 17) and p53D5-6/D5-6RictorD/D (n = 22).
Over 80% of the tumor samples have extensively high level of Atoh1 expression, a signature of SHH MBs.
The visualization of the primary antibodies in immunofluorescence was performed with the use of the Alexa488, Alexa555 and
Alexa647 conjugated secondary antibodies (1:400, Invitrogen, Life Technologies). Primary antibodies used for immunofluorescence
were: p53 (1:500, rabbit, Leica), BrdU (1:500, rat, Abcam), Olig2 (1:2,000, rabbit, Millipore), Ki67 (1:500, rabbit, Abcam), Ascl1 (1:100-
1:200, mouse, BD PharMingen), GFAP (1:1,000-1:2,000, rabbit, Dako), Nestin (1:100, mouse, Millipore), Sox2 (1:250, goat, Santa
Cruz Biotech), Pax6 (1:500, rabbit, Covance), Calbindin (1:1000, mouse, Sigma) and NeuN (1:500, mouse, Millipore). For pAktS473
(1:300, rabbit, Cell Signaling) staining, biotin-conjugated secondary antibody was used, followed by signal amplification with
Alexa555-conjugated streptavidin (Thermo Fisher Scientific, S-32355). DAPI was used as a counterstain to label individual cell nuclei.
Sections were examined under a fluorescent microscope (Olympus BX53).
BrdU Assay for the Analyses of Proliferation and Differentiation
For the proliferation assay, mice were injected with 50 mg of BrdU per gram of body weight. Embryonic and newborn mice received
one injection, pups and neonatal mice up to 30 days old received two, mice around two months old received three and adult mice
older than twomonths old received five injections, with multiple injections applied at two hour-intervals. All of themice were perfused
with 4% PFA two hours after the final BrdU injection. For the differentiation assay, P15 mice were injected with a 50 mg of BrdU per
gram of body weight pulse and perfused with 4% PFA following a 48-hour chase. In both assays, brains were dissected and
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processed for either paraffin-embedded or cryostat sections. BrdU immunofluorescence was performed as described previously
(Wang et al., 2009).
BKM120 Treatment Study
The wild-type pups were injected with 10mg/KG BKM120 (Selleckchem, S2247) or Vehicle (10% Kolliphor EL (Sigma-Aldrich,
C5135), 10% PEG400 (Sigma-Aldrich, 202398)) daily from P8 to P16. After the injection at P16, the mice were injected with 50 mg
of BrdU per gram of body weight for two times at two hour-intervals. Then the mice were collected as mentioned above.
Identification of p53D5-6-positive Early Tumor Precursors for Malignant Glioma and Medulloblastoma
Early glioma precursors are defined as p53D5-6-positive cell clusters (> 20 cells per high magnification view) in brain regions (e.g.,
corpus callosum) outside the SVZ/RMS germinal zone in 4-7 month old p53D5-6/D5-6 brains. Early medulloblastoma precursors
are defined as p53D5-6-positive cell clusters (> 10 cells per high magnification view) in the ‘‘persistent’’ EGL in the cerebella of
p53D5-6/D5-6 (with or without Rictor deletion) at the age of P22 or older. At these time points, there is almost no proliferation in afore-
mentioned brain regions in control mice. In p53D5-6/D5-6 (with or without Rictor deletion) brains, although not all the p53D5-6-positive
cells in the cluster are BrdU+, themajority of BrdU+ abnormal proliferating cells are p53D5-6-positive, which provides the basis of using
the p53D5-6 marker to label the early tumor precursor cells in the morphologically normal brains.
Western Blotting Analysis
Snap-frozen tissue samples from wild-type control brains and tumors were homogenized in Pierce RIPA Buffer (Thermo Fisher Sci-
entific) (10 mL buffer/1 mg tissue), mixed 1:1 with Laemmli Sample Buffer (BioRad) and boiled at 100C for 8 minutes. Samples were
then subjected to SDS-PAGE using the Criterion TGX Precast gels (BioRad) and transferred onto PVDF membranes (Millipore). The
membranes were blocked in 5% non-fat milk prepared in TBST and prior to an overnight incubation with primary antibodies at 4C.
Next the membranes were washed with TBST and incubated in horseradish peroxidase (HRP)-conjugated secondary antibodies at
room temperature for 1 hour. Signal was detected using Pierce ECL Western Blotting Substrate (Thermo Fisher Scientific). The pri-
mary antibodies used in this study were as follows: pAktS473 (1:1,000, rabbit, Cell Signaling), pAktT308 (1:1,000, rabbit, Cell Signaling),
Akt (1:1,000, rabbit, Cell Signaling), pNDRG1T346 (1:1,000, rabbit, Cell Signaling), Pten (1:1,000, rabbit, Cell Signaling), Rictor (1:500,
rabbit, gift from Dr. D. Fingar at University of Michigan), mTOR (1:1,000, rabbit, Cell Signaling), b-Actin (1:5,000-10,000, mouse,
Sigma-Aldrich), pS6KT389 (1:1,000, rabbit, Cell Signaling), p4E-BP1T37/46 (1:1,000, rabbit, Cell Signaling), pTSC2T1462 (1:1,000, rabbit,
Cell Signaling), pS6S240/244 (1:2,000, rabbit, Cell Signaling), S6 (1:2,000, rabbit, Cell Signaling), Olig2 (1:4,000, rabbit, Millipore), cMyc
(1:1,000, rabbit, Cell Signaling), pErk1/2T202/Ty204 (1:1,000, rabbit, Cell Signaling), Erk1/2 (1:1,000, rabbit, Cell Signaling), pGSK-3bS9
(1:2,000, rabbit, Cell Signaling), P120 (1:1000, mouse, BD Biosciences), Pax6 (1:1,000, rabbit, Covance), Gli1 (1:500, rabbit,
Cell Signaling) and Ezh2 (1:1,000-1:2,000, rabbit, Cell Signaling) and Atoh1 (1:1000, Rabbit, Abcam, ab168374). HRP-conjugated
secondary antibodies were anti-mouse (1:5,000-1:10,000, goat, BioRad) and anti-rabbit (1:5,000-1:10,000, goat, BioRad).
Tumor-Sphere Cell Culture and Chromosome Assay
End-stage tumors were dissected at 4C and tissue was then transferred into DMEMmedium, followed by enzymatic cell dissociation
using Accutase (Innovative Cell Technologies). Cell cultures were prepared in self-renewal medium based on an established protocol
(Wang et al., 2012). Cell density was quantified using a hemocytometer, (Counting Chamber, Hausser Scientific) and approximately
20,000-100,000 cells/well were plated into 6-well ultra-low attachment surface polystyrene plates (Corning) for primary tumor-sphere
cultures. The medium was changed every 3-5 days and the cultured cells were passaged into two new 6-well plates after 1-2 weeks
based on the growth rate and passage number. Chromosomeanalyseswere conducted using primary cell lines based on ametaphase
preparation protocol as previously described (Frappart et al., 2009). According to this protocol, cells were grown for 24 hours, treated
with 100 ng/ml KaryoMaxColcemid solution (GIBCO, Life Technologies) for 1 hour to arrest proliferation atmetaphase. Cells were then
treated with 0.4% KCl at 37C, fixed in ice cold Methanol:Glacial acetic acid (3:1) solution overnight and dropped on Superfrost Plus
microscope slides (Fisher Scientific). Chromosomes ofmetaphase cells were stainedwithDAPI. Cell lines analyzed at passage 1 and 2
are considered ‘‘early passage’’ and those analyzed at subsequent passages are considered as ‘‘late passage.’’
RT-PCR for Copy Number Analyses
Total genomic DNAs were extracted from frozen wild-type control brain tissues, high-grade gliomas andmedulloblastomas by using an
AllPrepDNA/RNAMiniKit (QIAGEN).Dependingonthesampleconcentration,variousamountsof templateDNA(average100ng/reaction)
alongwith the SYBRSelectMasterMix (Thermo Fisher Scientific) and primers were used in RT-PCR. See primer information in Table S2.
DCT value (CTtestGene - CTreference) and then [1/CT
2] is calculated for each sample. The average of the readings from the wild-type
control tissue were set to ‘‘1’’ and all of the samples were calculated accordingly. b-Actin (chr5) and Gapdh (chr7), and Tfrc (chr16)
were used as reference genes (internal controls). We additionally used TaqMan Copy Number Assays along with the compatible
CopyCaller Software. Tfrc (chr16) was used as a reference gene in this set of analyses. The primer sets were as follows:
N-Myc
Mycn_Mm00378993_cn
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Gli2
Gli2_Mm00026939_cn
Tfrc
TaqMan Copy Number Reference Assay, mouse, Tfrc
The estimated copy numbers based on b-Actin, Gapdh, and Tfrc were compared to each other to confirm the accuracy and the
consistence of the copy number calculations. Then, the average of the three readings were shown in the figures.
RT-PCR for Gene Expression Analyses
cDNA synthesis, using RNA collected as described, was performed using QuantiTect Reverse Transcription Kit (QIAGEN), along with
approximately 300ng of RNA for each sample. RT-PCR experiments were carried out in the 7500 Real-Time PCR System (Applied
Biosystems) using SYBR Select Master Mix (Applied Biosystems) and primers. See primers information in Table S2.
DCT value (CTtestGene - CTGapdh) and then [1/CT
2] is calculated for each sample. The average of the readings from the Ptch1+/
model medulloblastomas was set to ‘‘100’’ and all of the samples were calculated accordingly. Wild-type control brain tissue and
gliomas were used as negative controls for medulloblastoma samples.
Protein half-life analysis of Atoh1
A p53D5-6/D5-6 medulloblastoma cell line (CKO2 L2) was treated with 200 mg/ml cycloheximide (Sigma, C7698-1G) together with
vehicle (DMSO), BKM120 and MLN4924 (Selleckchem, S7109) as indicated. Then the cells were collected at indicated time points
for IB assay. The Atoh1 level was quantified by densitometry analysis using ImageJ (1.50i) image processing software. The ratio of
Atoh1/b-Actin was calculated and statistical analysis was performed using Prism 7 with Two-way ANOVA analysis.
Bioinformatics
Affymetrix GeneChip Mouse Genome 430 2.0 Array was used for the gene expression profiles of the glioma and medulloblastoma
samples. Unsupervised hierarchical cluster analyses were performed in categorization of the samples. Agilent 44K/100K cDNA
and/or oligochip were used for the copy number analyses of the glioma samples. The genotypes of the MB samples used in these
analyses are: p53D/D (n = 3), p53D5-6/D5-6Rictor+/D (n = 2), p53D5-6/D5-6RictorD/D (n = 5), p53D5-6/D5-6Pten+/D (n = 3), p53D5-6/D5-6Pten+/D
Rictor+/D (n = 6, three of which had germline Rictor mutation), and p53D5-6/D5-6Pten+/DRictorD/D (n = 3).
Low-coverage whole genome sequencing (lgWGS) was used to infer the copy number changes in mouse medulloblastomas. The
read counts per 1kb along each gene’s chromosomal region is plotted, and the copy number changes in tumor samples were calcu-
lated in comparison to matched tail DNA.
The Kaplan scanner tool in R2 was used to find the best cut-off in expression within a certain group of tumors for which the Kaplan
Meier analysis gives the lowest log rank p value. This p value was corrected for multiple testing as multiple tests were performed to
find the lowest p value. The plots that we showed in Figure 7 and Figure S8 were thus the plots with lowest p values. All other cut-offs
gave higher p values. Of course, the cut-offs can then be different between each subgroup. However, as overall expression levels are
also different between subgroups, it still makes sense to use different cut-offs. R2 is a microarray analysis and visualization platform
that is freely available online: https://hgserver1.amc.nl/cgi-bin/r2/main.cgi.
Schematic representations of the mouse chr19 and chr7, and human chr10 were prepared based on the information in Ensembl
database.
QUANTIFICATION AND STATISTICAL ANALYSIS
Kaplan-Meier survival curves were used to compare the survivorship of themice sacrificed due to brain tumors, soft tissue sarcomas
and/or other health concerns. The Mantel-Cox (Log-rank) test was used to compare the curves statistically. Anatomically compara-
ble sections from control and mutant brains were visualized at 20X and 40X magnifications. Multiple images were captured and sub-
jected to double-blinded analysis to measure the specific areas (i.e., cerebellar surface area) and to quantify the number of the cells
using ImageJ software. At least three animals were used from each group, and two-tailed Student’s t test was used to compare the
number and percentage of the different cellular populations. Fisher’s exact test was used to compare the mouse models in terms of
the tumor location and tumor spectrum. Linear regression analysis was performed in RT-PCR experiments for copy number
estimates comparing the readings based on two different reference genes. The coefficient of determination (R2) and p values
were calculated. Data were presented as mean ± Standard Deviation (SD) or Standard Error of the Mean (SEM), and p < 0.05 was
considered to be statistically significant in all of the statistical analyses.
DATA AND SOFTWARE AVAILABILITY
The accession number for the gene expression data reported in this paper is GEO: GSE78895.
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Figure S1 
 
		
Figure S1, related to Figure 1. p53-mutant GEM malignant gliomas are characterized by the key molecular events frequently observed in 
human GBMs.  
(A) Synteny map comparing the human chr7 with the mouse chr5, chr6, and chr11. The locations of the PDGFA/Pdgfa, MET/Met, and 
EGFR/Egfr genes are indicated in both human and mouse chromosomes.  
(B) Heatmap representation of the copy number alterations (CNAs) in Egfr and Met genes in GEM malignant gliomas. One case (sample #3) 
with Egfr focal amplification, a characteristic event for Classical subtype, was the only case that strongly expressed the Classical subtype 
signature. The amplified segment roughly covers 1,080 kb with log2Ratio=4.77, as shown in the following Integrative Genomics Viewer 
(IGV) screenshot (C). This magnitude of amplification is common in human GBMs. There was another case that had Egfr gain (sample #23). 
It not only strongly expressed the Proneural signature, but also expressed a secondary Classical signature, as shown in Figure 1A. We used 
discrete copy number values (-2, -1, 0, 1, 2), representing homozygous deletion, hemizygous deletion, copy number neural, gain, and high-
level amplification. These discrete values were obtained by analyzing the segmentation distribution of each sample. The case associated with 
Classical subtype and another sample with Classical signature but associated with a dominant Proneural subtype are indicated with arrows. 
Gene deletions are shown in blue, gene amplifications are shown in red.  
(C) IGV heatmap representation of the copy number changes around a region in chr11 of the 23 GEM malignant gliomas. The location of the 
Egfr gene within this region is indicated with dashed boxes for two samples with high-level focal Egfr amplification (sample #3) or low-level 
amplification/gain (sample #23).  
(D-F) IGV heatmap representation of the copy number changes in human GBMs (from TCGA, D), malignant gliomas (n = 23) from GEM 
models used in this study (E) and malignant gliomas from GEM models from a previously published study (Chow et al., 2011) (F) are 
shown. Human chr10 and chr19 are highlighted with solid box. Segments of the mouse chr19 and chr7 (syntenic to human chr10q) and 
mouse chr7 (syntenic to human chr19) are indicated with dashed boxes.  	 	
Figure S2 
 
		
Figure S2, related to Figure 2. Histopathological and molecular features of the p53-mutant driven malignant gliomas.  
(A) Brain tumor penetrance is shown by the ratio of ‘the number of the mice sacrificed due to brain tumors’ to ‘the total number of mice 
analyzed within the cohorts’. Mice without brain tumors were sacrificed due to other health-concerning reasons, including soft-tissue 
sarcomas, paralysis, spinal cord tumors, eye problems, prolapse, dermatitis and other poor health conditions. Fisher’s exact test was used to 
compare the groups in terms of the frequency of mutant mice ‘with brain tumors’ versus ‘without brain tumors’.  
(B) Kaplan-Meier survival curves of the mice that were sacrificed due to body tumor formation without any brain tumors or brain 
abnormalities. The Mantel-Cox (Log-rank) test was used to compare the survival curves statistically.  
(C) Histopathological analyses of p53Δ5-6 driven malignant gliomas using p53, Olig2, GFAP and Synaptophysin antibodies. Multipolar or 
abnormal mitoses (i, iii and xii), multinucleated giant cells (ii, iv, vi, vii and xiv), mitotic figures (x and xiii), and vascular proliferation (xv) are 
noted.  
(D) The total number of the p53Δ5-6-positive cells remaining in the germinal zone (SVZ/RMS) was quantified in 6-7 months old p53Δ5-6/Δ5-6 
and p53Δ5-6/Δ5-6RictorΔ/Δ mice. The proliferation percentages of the p53Δ5-6-positive cells (i.e. BrdU+p53Δ5-6-positive/p53Δ5-6-positive) were 
calculated using samples with at least 10 or more p53Δ5-6-positive cells.  
(E) Genotyping of the malignant glioma samples from p53Δ5-6/Δ5-6, p53Δ5-6/Δ5-6Rictor+/Δ, and p53Δ5-6/Δ5-6RictorΔ/Δ mice. Normal brain tissue 
from a hGFAP-cre;p53+/flox;Rictor+/flox mouse was used as a positive control (Ctr) to show the PCR bands of wild-type allele and floxed allele 
of p53 and Rictor genes. Cre-negative normal brain tissue was used as a negative control (Ctr) for the PCR band of Cre allele.  
(F) Western blot analysis of the malignant gliomas from p53Δ5-6/Δ5-6 (n = 4), p53Δ5-6/Δ5-6Rictor+/Δ (n = 8), and p53Δ5-6/Δ5-6RictorΔ/Δ (n = 8) mice 
along with a normal cerebral cortex tissue (CTR) and malignant gliomas from the glioma model that harbors p53 and Pten mutations (p53Δ5-
6/Δ5-6Pten+/Δ, details about this model is shown in Figure S3D). 
All quantification data are presented as mean ± SEM. Two-tailed Fisher’s exact test was used to compare the groups (A). The Mantel-Cox 
(Log-rank) test was used to compare the survival curves statistically (B). Scale bars, 25 µm. 		
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Figure S3, related to Figure 3. Analyses of Rictor-deficient MBs in comparison with various mouse models.  
(A) Western blot analysis of mTORC1 signaling pathway in p53Δ5-6/Δ5-6, p53Δ5-6/Δ5-6Rictor+/Δ, and p53Δ5-6/Δ5-6RictorΔ/Δ MB samples along with 
various Ptch1+/- MBs (Ptch+/-, p53Δ5-6/Δ5-6Ptch1+/-, and p53R172P/Δ5-6Ptch1+/-). Wild-type cerebellar tissue was used as a control (CTR), and two 
malignant glioma samples from p53Δ5-6/Δ5-6Rictor+/Δ and p53Δ5-6/Δ5-6Pten+/Δ (last two lanes) mice were also included in the analysis. 
(B) Brain tumor distribution and survival curves of p53-mutant mice with brain tumors among different cohorts. Note that mice with MBs 
(labeled with “blue/green-like” curves) succumbed to death earlier than the mice with malignant glioma (labeled with “pink/red-like” curves) 
in all cohorts and models. In addition, the penetrance of the MBs is less than 11% in all models, except for p53Δ5-6/Δ5-6RictorΔ/Δ, which has up 
to 52% MB penetrance. Lastly, p53Δ5-6/Δ5-6RictorΔ/Δ mice with malignant gliomas lived significantly longer than any of the other p53-mutant 
mouse models with malignant gliomas (comparison of pink/red curves), p < 0.0001. 
(C and D) Genetic configuration of p53Δ5-6/Δ5-6, p53Δ5-6/Δ5-6Rictor+/Δ, and p53Δ5-6/Δ5-6RictorΔ/Δ mice (C) and p53Δ5-6/Δ5-6Pten+/Δ, p53Δ5-6/Δ5-
6Pten+/ΔRictor+/Δ, and p53Δ5-6/Δ5-6Pten+/ΔRictorΔ/Δ mice (D). Floxed alleles undergo hGFAP-cre mediated recombination in radial glial cells of 
the developing cerebral cortex at around embryonic day 12.5 (E12.5).  
(E and F) The frequency (E) and scatter plot representation (F) of malignant gliomas and MBs in the p53Δ5-6/Pten+/Δ-mutant driven models 
with three different Rictor genotypes. Note the MB frequency is significantly increased in p53Δ5-6/Δ5-6Pten+/ΔRictorΔ/Δ mice. 
(G) Histopathological analysis of the malignant gliomas from p53Δ5-6/Δ5-6Pten+/Δ and p53Δ5-6/Δ5-6Pten+/ΔRictor+/Δ mice, and MBs from p53Δ5-
6/Δ5-6Pten+/ΔRictor+/Δ and p53Δ5-6/Δ5-6Pten+/ΔRictorΔ/Δ mice. Note the striking difference in cellularity and Olig2 immunoreactivity between the 
malignant gliomas and MBs, as seen in human tumors.  
The Mantel-Cox (Log-rank) test was used to compare the survival curves statistically (B). Two-tailed Fisher’s exact test was used to compare 
the MB frequency in different GEM models (E). Scale bars, 50 µm. 		
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Figure S4, related to Figure 4. Rictor/mTORC2 signaling is essential for timely differentiation of a subset of GCPs.  
(A and B) The expression levels of Gli1, Atoh1, Boc, and Sfrp1 genes from microarray data in p53-mutant driven MBs (with or without 
additional Pten and Rictor mutations) and malignant gliomas, previously published GEM models of WNT, SHH, and Group 3 MBs, GCPs, 
and normal cerebellar tissues were compared. p53-mutant driven MBs with possible normal tissue contamination are labeled as “p53-mut MB 
(contam.)”. p-values of several group comparisons are shown in (B).  
(C) Gene expression levels of Gli1, Gli2, Atoh1, and Sfrp1 from microarray data were examined in relation to Rictor status in p53-mutant 
driven MBs.  
(D and E) Control and mutant mice at P16 were injected with BrdU and analyzed two hours later. The total surface area (mm2) (D) and the 
total number of BrdU+ proliferating cells (E) were calculated for each of the wild-type control and mutant cerebella.  
(F) Several group comparisons related to Figure 4I are presented with a table. 
(G-L) P22 control and mutant mice were injected with BrdU and sacrificed two hours later.  
(G-I) High magnification views of Folia-5/6 (G), Folia-9/10a (H), and Folia-10b (I) illustrate the BrdU+ proliferating cells, Pax6+ neural 
lineage cells, and NeuN+ differentiated neurons in P22 cerebella. Two types of Rictor-deficient mutant mice are highlighted by red dashed 
boxes. 
(J-L) The total number of the Pax6+ cells that were located in ML (J) or proliferating in EGL-associated areas (K) was quantified in three 
folia (Folia-5/6, Folia-9/10a, and Folia-10b).  p-values for several comparisons are shown in (L). 
All quantification data presented as mean ± SEM. Unpaired Student’s t-test was used to compare the groups statistically. Scale bars, 100 µm. 
EGL, External Granular Layer; ML, Molecular Layer; IGL, Internal Granular Layer. 
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Figure S5, related to Figure 5. Inhibition of PI3K/Akt signaling resembles Rictor deficiency phenotype in developing mouse brain.  
(A) P8 control and RictorΔ/Δ cerebella were co-stained with pAktS473 and lineage-specific markers NeuN (granule neurons), GFAP (Bergmann 
glial cells), and Calbindin (CalB, Purkinje cells). DAPI labels the nuclei. Arrows indicate the differentiated neurons with robust pAktS473 
expression in IGL.  
(B) pAktS473 was co-labeled with NeuN (granule neurons) in adult wild-type control cerebellum. DAPI is shown in blue.  
(C-E) Wild type mice were treated with vehicle or BKM120 (10uM) from P8 to P16. Analyses were performed at P16. 
(C) Body weights of vehicle- or BKM120-treated mice were measured daily between P8-P16.  
(D and E) Representative whole-mount images of brains collected from vehicle- or BKM120-treated brains (D), and their weight at P16 (E).  
(F-H) Body weights (F) and brain weights (H) of the wild-type control, p53+/Δ5-6RictorΔ/Δ, and p53Δ5-6/Δ5-6RictorΔ/Δ mice at P8, P16, P22 and, 
4-months (P120). G, Whole-mount images of brains collected from 4-months old wild-type control, p53+/Δ5-6RictorΔ/Δ, and p53Δ5-6/Δ5-
6RictorΔ/Δ mice.  
(I and J) Total Ki67+ cell number was quantified in all EGLs (I) and only in Folia-6&7 (J), related to Figure 5C.  
(K and L) Representative H&E staining of cerebella from vehicle- or BKM120-treated mice. Areas marked with Roman numbers indicate 
Folia-6, Folia-7, and Folia-8 (K). High magnification images of marked areas in F-6a/6b, F-6b/7, and F-7/8 are also shown (L). Arrowheads 
indicate the retained cells in EGL. 
(M) p53Δ5-6/Δ5-6	 medulloblastoma cell line was treated with DMSO and BKM120 (0.1µM) for different time periods as indicated. Then, 
CellTiter-Glo luminescent cell viability analysis was performed. For each time point, the ratio of BKM120 group/DMSO group was 
calculated.  
(N) p53Δ5-6/Δ5-6	medulloblastoma cell line was treated with BKM120 (0.1µM) for different time periods as indicated. Then, the cells were 
collected and subjected to -qPCR analysis to determine Atoh1 mRNA levels. Four repeated experiments were analyzed. 
All quantification data presented as mean ± SEM. Unpaired Student’s t-test was used to compare the groups statistically in (C, E, F, H, I, J). 
Scale bars, 1 mm (D and G), 250 µm (K), 100 µm (A), and 50 µm (B and L). EGL, External Granular Layer; ML, Molecular Layer; IGL, 
Internal Granular Layer. 
 
 
 
 
 
 
 
 
 
Figure S6 
Figure S6, related to Figure 6. p53-mutant driven MBs share critical features of TP53-mutant SHH-MBs in humans 
(A-C) The total number of BrdU+ cells (A) and p53Δ5-6-positive cells (B) over three time points – P16, P22, and P60 – were quantified. The 
percentage of proliferating p53Δ5-6-positive cells among the entire proliferating population (BrdU+p53Δ5-6-positive/BrdU+) was calculated (C). 
(D) Examples of clustered BrdU+p53Δ5-6-positive cells in p53Δ5-6/Δ5-6RictorΔ/Δ cerebella at P60. Arrows indicate BrdU+p53Δ5-6-positive cells, 
arrowheads indicate BrdU+p53- cells.  
(E) Frequency of Ptch1 bi-allelic inactivation across different mouse MB models. Dark blue bars indicate the samples with homozygous 
Ptch1 deletion while light blue bars indicate the samples with concurrent heterozygous Ptch1 deletion and Ptch1 mutation. White bars 
indicate samples with at least one intact Ptch1 allele (i.e. wild type or heterozygous Ptch1). 
(F) Low-coverage whole genome sequencing (lcWGS) plots depicting the copy number alterations (CNAs) in chr12, chr1, and the entire 
genome of p53-mutant driven MBs. The low-level N-Myc amplification/gain (sample G3), chr12 gain (samples C4 and E1), and low-level 
Gli2 amplification/gain (sample B4) are colored in red. X-axes specify the location within each chromosome. Y-axes indicate the number of 
read per 1 kb normalized to total reads. This parameter is shown as a ratio of tumor versus control tissue. Baseline is shown with a red line 
across the plots. Red frames label the chromosomal regions with gains/amplifications. (G-L) lcWGS plots of whole genome or chr13 and 
chr19 in two p53-mutant driven mouse MBs with Rictor deletions. X-axes specify the location within each chromosome. Y-axes indicate the 
number of read per 1 kb normalized to total reads. This parameter is shown as a ratio of tumor versus control tissue. Baseline is shown with a 
red line across the plots. Blue shades and frames label the chromosomal regions with losses while the red shades and frames label the 
chromosomal regions with gains/amplifications. chr13 and chr19 are framed by blue and/or red rectangles in (G and J), and they are shown 
in higher magnification (H and K for chr13 and I and L for chr19). The approximate locations of Ptch1 (H and K) and Pten (I and L) genes 
are indicated with arrows. 
(M) The frequencies of each copy number alterations exemplified in (F-L) were calculated and presented in relation to their Rictor genotype. 
The actual numbers of the events are shown, and the ratios are presented as percentages in parentheses.  
Fisher’s exact test was used to compare the groups statistically in (E). Scale bars, 50 µm. EGL, External Granular Layer. 
 
 
 				
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S7 
 
		
Figure S7, related to Figure 6. p53-mutant driven MBs display distinct chromosomal and genomic features.  
(A and B) Karyotyping assay was performed to examine the overall chromosomal structure and chromosome number in early-passage 
(passage number ≤ 2) p53Δ5-6/Δ5-6RictorΔ/Δ MB cell lines. Head-to-head fusions (i, ii, iv, v and vi), head-to-tail fusions or translocations (iv) 
and centromere loss (iii) are pointed with red arrowheads (A). The chromosome numbers were quantified in p53Δ5-6/Δ5-6RictorΔ/Δ (n = 9) and 
p53Δ5-6/Δ5-6Rictor+/Δ (n = 1) MB cell lines. The cells with clear aneuploidy are shown with red dots while others with diploid genomes are 
shown in black (B).  
(C) Schematic representation of the opposing roles of Rictor/mTORC2 signaling in p53Δ5-6-mutant driven brain tumorigenesis. 
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Figure S8, related to Figure 7. RICTOR expression, but not other components of mTORC2 and mTORC1, is correlated with opposite 
clinical outcomes in pediatric SHH-MBs versus adult non-G-CIMP primary GBMs.  
(A, D, and G) Scatter plot representation of SIN1 (MAPKAP1) (A), MTOR (D), and RPTOR (G) expression among the pediatric (infant and 
childhood) and adult SHH-MB samples.  
(B and C) Overall survival probability of the pediatric (B) and adult (C) patients with SHH-MBs in relation to SIN1 expression.  
(E and F) Overall survival probability of the pediatric (E) and adult (F) patients with SHH-MBs in relation to MTOR expression.  
(H and I) Overall survival probability of the pediatric (H) and adult (I) patients with SHH-MBs in relation to RPTOR expression.  
(J) Overall survival probability of the non-G-CIMP GBM patients (with less than 7 months follow-up) based on their RICTOR expression.  
(K-M) Overall survival probability of the GBM patients based on their SIN1 (K), MTOR (L), and RPTOR (M) expression.  
Anova test was used to compare the groups statistically in (A, D and G). Multiple corrected log-rank tests between pairs of groups are used 
for comparisons of survival curves in (B, C, E, F and H-M). The individual data sets are initially scanned to find the cut-off in expression 
that results in the lowest p-value between high and low expression values.
